Could efgartigimod tame lupus nephritis? early trial hints at hope

NCT ID NCT05810948

Completed Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested the drug efgartigimod in 73 Chinese patients with active lupus nephritis, a serious kidney complication of lupus. Participants received either the drug or a placebo by IV infusion over 24 weeks. The main goal was to see if the drug could reduce protein in the urine, a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efgartigimod (a drug given by IV infusion that targets the immune system)
What this could lead to: If it works, this could point toward a new treatment option for lupus nephritis, potentially helping control kidney inflammation and reduce protein in urine.
What could go wrong: This is an early proof-of-concept study with only 73 participants, so results may not be conclusive. The drug may not show clear benefit over placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glomerulonephritis kidney disorder lupus nephritis nephritis urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Affiliated Hospital of Jining Medical University

Jining, China
First Affiliated Hospital of University of South China

Hengyang, China
Fujian Medical University Union Hospital

Fujian, China
Guangdong Provincial People's Hospital

Guangzhou, China
Henan Provincial People's Hospital

Zhengzhou, China
Huashan Hospital Fudan University

Shanghai, China
Hunan Provincial People's Hospital

Changsha, China
Jiangsu Province Hospital

Nanjing, China
Jiangxi Provincial People's Hospital

Nanchang, 330006, China
Jieyang People's Hospital

Jieyang, 522091, China
Liu Zhou Works Hospital

Liuzhou, China
Peking University People's Hospital

Beijing, China
Peking University Third Hospital

Beijing, 100191, China
Renmin Hospital of Wuhan University

Wuhan, China
Shaanxi Provincial Hospital of Chinese Medicine

Xi'an, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University

Jinan, China
ShengJing Hospital of China Medical University

Shenyang, China
Shenzhen People's Hospital

Shenzhen, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, China
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University

Huainan, China
The First Affiliated Hospital of Nanchang University

Nanchang, China
The First Affiliated Hospital of Xiamen University

Xiamen, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, 310058, China
The First Affiliated Hospital, Zhejiang University

Hangzhou, China
The First Affiliated Hospital,Sun Yat-sen University

Guanzhou, China
The First Hospital of Hebei Medical University

Shijia Zhuang, China
The People's Hospital of Guangxi Zhuang Autonomous Region

Nanning, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, China
The Second Hospital of Tianjin Medical University

Tianjin, China
Wuxi People's Hospital

Wuxi, China
Zhongda Hospital Southeast University

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.